143 related articles for article (PubMed ID: 36057012)
1. Semiquantitative analysis using whole-body dynamic F-18 fluoro-2-deoxy-glucose-positron emission tomography to differentiate between benign and malignant lesions.
Watanabe M; Kato H; Katayama D; Soeda F; Matsunaga K; Watabe T; Tatsumi M; Shimosegawa E; Tomiyama N
Ann Nucl Med; 2022 Nov; 36(11):951-963. PubMed ID: 36057012
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
4. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
5. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI.
Schaarschmidt BM; Buchbender C; Nensa F; Grueneisen J; Gomez B; Köhler J; Reis H; Ruhlmann V; Umutlu L; Heusch P
PLoS One; 2015; 10(1):e0116277. PubMed ID: 25574968
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head intra-individual comparison of total-body 2-[
Chen X; Hu P; Yu H; Tan H; He Y; Cao S; Zhou Y; Shi H
Eur Radiol; 2023 Nov; 33(11):7890-7898. PubMed ID: 37338551
[TBL] [Abstract][Full Text] [Related]
7. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Shin DS; Shon OJ; Byun SJ; Choi JH; Chun KA; Cho IH
Skeletal Radiol; 2008 May; 37(5):415-21. PubMed ID: 18309481
[TBL] [Abstract][Full Text] [Related]
8. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.
Basu S; Kung J; Houseni M; Zhuang H; Tidmarsh GF; Alavi A
Q J Nucl Med Mol Imaging; 2009 Feb; 53(1):9-19. PubMed ID: 18337683
[TBL] [Abstract][Full Text] [Related]
9. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions.
Nakayama M; Okizaki A; Ishitoya S; Sakaguchi M; Sato J; Aburano T
Ann Nucl Med; 2013 Feb; 27(2):163-9. PubMed ID: 23188388
[TBL] [Abstract][Full Text] [Related]
10. [
Zheng S; Chen Z; Huang C; Chen Y; Miao W
Ann Nucl Med; 2019 Feb; 33(2):135-143. PubMed ID: 30392070
[TBL] [Abstract][Full Text] [Related]
11. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of dynamic
Sun Y; Xiao L; Wang Y; Liu C; Cao L; Zhai W; Wang B; Yu S; Xin J
Quant Imaging Med Surg; 2023 Apr; 13(4):2556-2567. PubMed ID: 37064404
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous whole body (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with (18)F-fluorodeoxyglucose positron emission tomography computed tomography.
Pugmire BS; Guimaraes AR; Lim R; Friedmann AM; Huang M; Ebb D; Weinstein H; Catalano OA; Mahmood U; Catana C; Gee MS
World J Radiol; 2016 Mar; 8(3):322-30. PubMed ID: 27028112
[TBL] [Abstract][Full Text] [Related]
14. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes.
Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D
Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845
[TBL] [Abstract][Full Text] [Related]
15. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.
Heusch P; Buchbender C; Beiderwellen K; Nensa F; Hartung-Knemeyer V; Lauenstein TC; Bockisch A; Forsting M; Antoch G; Heusner TA
Eur J Radiol; 2013 May; 82(5):870-6. PubMed ID: 23394765
[TBL] [Abstract][Full Text] [Related]
16. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
[TBL] [Abstract][Full Text] [Related]
17. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
[TBL] [Abstract][Full Text] [Related]
18. Role of
Ma G; Zhang X; Wang M; Xu X; Xu B; Guan Z
Quant Imaging Med Surg; 2021 May; 11(5):2013-2018. PubMed ID: 33936982
[TBL] [Abstract][Full Text] [Related]
19. Differentiation and diagnosis of benign and malignant testicular lesions using 18F-FDG PET/CT.
Shao D; Gao Q; Tian XW; Wang SY; Liang CH; Wang SX
Eur J Radiol; 2017 Aug; 93():114-120. PubMed ID: 28668404
[TBL] [Abstract][Full Text] [Related]
20. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
